Los Angeles Capital Management LLC Buys 13,446 Shares of Eli Lilly and Company (NYSE:LLY)

Los Angeles Capital Management LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 446,994 shares of the company’s stock after acquiring an additional 13,446 shares during the quarter. Eli Lilly and Company makes up about 1.2% of Los Angeles Capital Management LLC’s portfolio, making the stock its 11th largest position. Los Angeles Capital Management LLC’s holdings in Eli Lilly and Company were worth $347,743,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. NBC Securities Inc. lifted its stake in shares of Eli Lilly and Company by 27.0% in the first quarter. NBC Securities Inc. now owns 4,770 shares of the company’s stock valued at $3,711,000 after buying an additional 1,013 shares in the last quarter. CWM LLC lifted its stake in shares of Eli Lilly and Company by 7.9% in the first quarter. CWM LLC now owns 68,862 shares of the company’s stock valued at $53,572,000 after buying an additional 5,041 shares in the last quarter. Moseley Investment Management Inc. lifted its stake in shares of Eli Lilly and Company by 0.4% in the first quarter. Moseley Investment Management Inc. now owns 3,890 shares of the company’s stock valued at $3,027,000 after buying an additional 14 shares in the last quarter. Advance Capital Management Inc. bought a new position in shares of Eli Lilly and Company in the first quarter valued at $223,000. Finally, Orrstown Financial Services Inc. lifted its stake in shares of Eli Lilly and Company by 2.6% in the first quarter. Orrstown Financial Services Inc. now owns 824 shares of the company’s stock valued at $641,000 after buying an additional 21 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 2,052 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total value of $1,660,068.00. Following the completion of the transaction, the insider now directly owns 98,554,195 shares in the company, valued at $79,730,343,755. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, major shareholder Lilly Endowment Inc sold 2,052 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total value of $1,660,068.00. Following the completion of the transaction, the insider now directly owns 98,554,195 shares in the company, valued at $79,730,343,755. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Johna Norton sold 7,056 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the sale, the executive vice president now owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 762,804 shares of company stock worth $648,109,138. 0.13% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Jefferies Financial Group raised their price objective on shares of Eli Lilly and Company from $925.00 to $957.00 and gave the company a “buy” rating in a research note on Friday, June 7th. Argus increased their target price on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. Truist Financial increased their target price on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a report on Wednesday, February 21st. Finally, BMO Capital Markets increased their target price on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $787.53.

Eli Lilly and Company Price Performance

LLY opened at $891.46 on Thursday. The company has a market capitalization of $847.25 billion, a price-to-earnings ratio of 131.29, a PEG ratio of 1.94 and a beta of 0.36. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The firm has a 50-day moving average price of $793.39 and a 200-day moving average price of $724.73. Eli Lilly and Company has a twelve month low of $434.34 and a twelve month high of $894.87.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company’s revenue was up 26.0% on a year-over-year basis. During the same quarter last year, the company earned $1.62 earnings per share. Equities analysts expect that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 10th. Stockholders of record on Thursday, May 16th were given a $1.30 dividend. The ex-dividend date was Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.58%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.